Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization Market: By Service Type (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Drug Development Service, Primary and Secondary Packaging Services, Biologics Manufacturing Services); Dosage Form-By State (Solid, Semi-Solid, Liquid Dose Formulation, Gas Dose Formulation); Route of Administration (Oral, Topical, Parenteral, Inhalations, Others); Indication (Cancer, Cardiovascular Disease, Diabetes, Pian, Respiratory disease, Others); End-User (Big Pharmaceutical Companies, Small & Medium-Sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Others); Country— Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2023–2031
Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market was valued at US$ 60.82 billion in 2022 and is projected to attain a valuation of US$ 140.03 billion by 2031, growing at a CAGR of 9.9% from 2023-2031. Read More
We Are Trusted By These Great Companies!
Published On: 14-Apr-2023 | Format: | Report ID: AA0423404